Press Release: Sanofi continues on path to industry leadership in
Immunology with Dupixent® (dupilumab) as key driver
Sanofi continues on path to industry leadership in Immunology
with Dupixent® (dupilumab) as key driver
- Dupixent peak sales ambition raised
to more than €13 billion
- Chronic obstructive pulmonary
disease 2023 pivotal readouts provide potential for additional
Dupixent sales ambition upgrade
- 13 potential new medicines
currently in the clinic to treat chronic inflammatory diseases,
with 17 readouts expected by the end of 2024
Paris,
March 28,
2022. Tomorrow, Sanofi will host an
Immunology Investor Event with key members of the leadership team
providing updates on how the company is advancing its Immunology
strategy, including the ambition to more than quadruple Immunology
franchise sales by the end of the decade. The focus of the event is
on Dupixent® (dupilumab), a key growth driver, and Sanofi’s rapidly
advancing pipeline, highlighting dermatological, respiratory and
gastrointestinal diseases as priority therapeutic areas. Sanofi has
raised the Dupixent sales peak ambition to more than €13 billion.
This new ambition does not include potential for additional sales
ambition upgrade from chronic obstructive pulmonary disease (COPD),
with pivotal readouts anticipated in 2023.
For more than a decade Sanofi, in collaboration
with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), has been
advancing the science of diseases driven by type 2 inflammation.
Dupixent is now a market leader and more than 400,000 patients with
certain types of atopic dermatitis (AD), asthma and chronic
rhinosinusitis with nasal polyposis have been treated globally. By
2025, Dupixent is expected to generate an additional 11 new
regulatory submissions across indications and age groups.
Bill SiboldExecutive Vice
President, Head of Global Specialty Care, Sanofi“In the five years
since launch, Dupixent has excelled in improving the lives of
patients with diseases driven by type 2 inflammation. This truly
unique medicine is only at the beginning of its journey to helping
potentially millions of patients. Beyond Dupixent, we are committed
to delivering the next generation of novel medicines that we hope
will change the practice of medicine in chronic inflammatory
diseases beyond type 2 inflammation. We are committed to moving
with the utmost urgency to bring new medicines to patients that
address their individual needs, offering choice and hope.”
Sanofi’s novel pipeline is comprised of 13
next-generation medicines designed to target mechanisms beyond type
2 inflammation. Our Research & Development (R&D) teams are
following the science to control chronic inflammation and
collaborating with leading experts across all sectors to address
both urgent and growing patient needs. We are focused on targets
with the most potential to alter the course of immune-based
diseases, from the mildest to the most severe, using novel
technologies that unlock previously inaccessible biology. These
drug discovery platforms, for example, synthetic biology, TAILORED
COVALENCY™ chemistry, and multispecific NANOBODY® molecules, are
allowing Sanofi to pursue both injectable and oral therapeutics.
Sanofi’s attack in immunological diseases also entails precision
medicine approaches that aim to remove the guess-work from clinical
practice by treating the right patients, with the right medicines,
at the right time.
John Reed,
M.D.,
Ph.D.Global
Head of Research and Development, Sanofi“Our long-term strategy
goes well beyond Dupixent to deliver best-in-class medicines that
break efficacy ceilings and help patients with chronic inflammatory
diseases achieve long-term disease modification. We are pursuing
this ambition through precision medicine approaches that leverage
our proprietary technologies, such as our NANOBODY platform that
can help us address multiple therapeutic targets with one medicine.
With approximately 21 clinical readouts expected across our
promising immunology pipeline by the end of next year, it is an
exciting time for our team working in Immunology R&D.”
Sanofi will highlight the following assets in
its growing R&D pipeline:
- Three candidates
for AD, complementing Dupixent’s position
in AD driven by type 2 inflammation, spanning all severities of
disease as well as topical, oral and injectable administration.
These drug development programs include our acceleration of
priority asset amlitelimab, an anti-OX40L antibody that aims to
restore immune homeostasis between pro-inflammatory and
anti-inflammatory T cells.
- Two
complementary candidates for
COPD, developed in collaboration with Regeneron, targeting
distinct subpopulations.
- A broad
Phase 1 clinical program of small molecules and
biologics. These candidate medicines include oral small molecules,
degraders, synthetic cytokines, and several NANOBODY molecules,
designed to simultaneously tackle two proven targets, thus aiming
to break efficacy ceilings.
Immunology Investor Event Details
The hybrid Immunology Investor Event will take
place on Tuesday, March 29 from 2 p.m. to 6 p.m. CEST / 8 a.m. to
noon EDT (webcast, in-person meeting at Sanofi’s Cambridge
office).
For background slides and webcast information,
please refer to the following link. The information will be
available beginning Tuesday, March 29 at 1 p.m. CEST / 7 a.m.
EDT.https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations/Immunology-Investor-Event-2022
About Our Inflammatory Pipeline
Through world-class R&D and a laser focus on
patients, Sanofi discovers, develops and delivers best-in-class
treatments that improve the lives of people living with chronic
inflammatory diseases. The Immunology pipeline consists of 7
potential new medicines in Phase 1 clinical development, 5 in Phase
2 clinical development, and 1 in Phase 3 clinical development.
These programs include potential treatments across a wide range of
inflammatory conditions. Dupilumab is being jointly developed by
Sanofi and Regeneron under a global collaboration agreement. In
addition to the 3 currently approved indications, Sanofi and
Regeneron are studying dupilumab in nearly a dozen other
diseases.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comPriya
Nanduri | +1 617 764 6418 |
priya.nanduri@sanofi.com Nathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that COVID-19 will have on us, our customers, suppliers,
vendors, and other business partners, and the financial condition
of any one of them, as well as on our employees and on the global
economy as a whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2021. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024